nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—ADRB2—prostate cancer	0.518	1	CbGaD
Labetalol—CYP2D6—Bicalutamide—prostate cancer	0.0543	0.504	CbGbCtD
Labetalol—CYP2D6—Abiraterone—prostate cancer	0.045	0.418	CbGbCtD
Labetalol—CYP2D6—Doxorubicin—prostate cancer	0.00832	0.0773	CbGbCtD
Labetalol—Dobutamine—COMT—prostate cancer	0.000589	0.0747	CrCbGaD
Labetalol—Salmeterol—CYP3A5—prostate cancer	0.000481	0.0611	CrCbGaD
Labetalol—Formoterol—CYP2A6—prostate cancer	0.000407	0.0517	CrCbGaD
Labetalol—Arformoterol—CYP2A6—prostate cancer	0.000407	0.0517	CrCbGaD
Labetalol—Benazepril—MTHFR—prostate cancer	0.000392	0.0498	CrCbGaD
Labetalol—Salmeterol—ADRB2—prostate cancer	0.00038	0.0483	CrCbGaD
Labetalol—Quinapril—ACE—prostate cancer	0.000367	0.0466	CrCbGaD
Labetalol—Ritodrine—ADRB2—prostate cancer	0.000366	0.0465	CrCbGaD
Labetalol—Fenoterol—ADRB2—prostate cancer	0.000366	0.0465	CrCbGaD
Labetalol—Arbutamine—ADRB2—prostate cancer	0.000343	0.0435	CrCbGaD
Labetalol—Formoterol—ADRB2—prostate cancer	0.000333	0.0422	CrCbGaD
Labetalol—Arformoterol—ADRB2—prostate cancer	0.000333	0.0422	CrCbGaD
Labetalol—Benazepril—ACE—prostate cancer	0.00032	0.0406	CrCbGaD
Labetalol—Dobutamine—ADRB2—prostate cancer	0.000315	0.04	CrCbGaD
Labetalol—Formoterol—CYP2C19—prostate cancer	0.000286	0.0363	CrCbGaD
Labetalol—Arformoterol—CYP2C19—prostate cancer	0.000286	0.0363	CrCbGaD
Labetalol—Ketoprofen—CXCL8—prostate cancer	0.00027	0.0342	CrCbGaD
Labetalol—Mirabegron—CYP3A4—prostate cancer	0.000228	0.0289	CrCbGaD
Labetalol—Salmeterol—CYP3A4—prostate cancer	0.000208	0.0264	CrCbGaD
Labetalol—Tolterodine—CYP2C19—prostate cancer	0.000188	0.0239	CrCbGaD
Labetalol—Isoprenaline—ADRB2—prostate cancer	0.000179	0.0227	CrCbGaD
Labetalol—Salsalate—PTGS2—prostate cancer	0.000161	0.0205	CrCbGaD
Labetalol—Isoprenaline—CYP1A1—prostate cancer	0.000153	0.0195	CrCbGaD
Labetalol—Body temperature increased—Mitoxantrone—prostate cancer	0.000138	0.000487	CcSEcCtD
Labetalol—Muscle spasms—Capecitabine—prostate cancer	0.000137	0.000485	CcSEcCtD
Labetalol—Flushing—Prednisone—prostate cancer	0.000136	0.000479	CcSEcCtD
Labetalol—Hypotension—Etoposide—prostate cancer	0.000135	0.000478	CcSEcCtD
Labetalol—Vision blurred—Capecitabine—prostate cancer	0.000135	0.000476	CcSEcCtD
Labetalol—Asthenia—Estradiol—prostate cancer	0.000134	0.000474	CcSEcCtD
Labetalol—Tremor—Capecitabine—prostate cancer	0.000134	0.000473	CcSEcCtD
Labetalol—Dysuria—Epirubicin—prostate cancer	0.000134	0.000472	CcSEcCtD
Labetalol—Fenoprofen—PTGS2—prostate cancer	0.000133	0.0169	CrCbGaD
Labetalol—Ill-defined disorder—Capecitabine—prostate cancer	0.000133	0.000468	CcSEcCtD
Labetalol—Syncope—Docetaxel—prostate cancer	0.000132	0.000467	CcSEcCtD
Labetalol—Pruritus—Estradiol—prostate cancer	0.000132	0.000467	CcSEcCtD
Labetalol—Palpitations—Docetaxel—prostate cancer	0.00013	0.000461	CcSEcCtD
Labetalol—Paraesthesia—Etoposide—prostate cancer	0.00013	0.00046	CcSEcCtD
Labetalol—Loss of consciousness—Docetaxel—prostate cancer	0.00013	0.000458	CcSEcCtD
Labetalol—Dyspnoea—Etoposide—prostate cancer	0.000129	0.000456	CcSEcCtD
Labetalol—Alopecia—Prednisone—prostate cancer	0.000129	0.000456	CcSEcCtD
Labetalol—Malaise—Capecitabine—prostate cancer	0.000129	0.000455	CcSEcCtD
Labetalol—Somnolence—Etoposide—prostate cancer	0.000129	0.000455	CcSEcCtD
Labetalol—Angina pectoris—Doxorubicin—prostate cancer	0.000129	0.000455	CcSEcCtD
Labetalol—Vertigo—Capecitabine—prostate cancer	0.000128	0.000453	CcSEcCtD
Labetalol—Hypersensitivity—Mitoxantrone—prostate cancer	0.000128	0.000453	CcSEcCtD
Labetalol—Syncope—Capecitabine—prostate cancer	0.000128	0.000453	CcSEcCtD
Labetalol—Mental disorder—Prednisone—prostate cancer	0.000128	0.000452	CcSEcCtD
Labetalol—Diarrhoea—Estradiol—prostate cancer	0.000128	0.000452	CcSEcCtD
Labetalol—Hypertension—Docetaxel—prostate cancer	0.000127	0.00045	CcSEcCtD
Labetalol—Drowsiness—Epirubicin—prostate cancer	0.000127	0.00045	CcSEcCtD
Labetalol—Erythema—Prednisone—prostate cancer	0.000127	0.00045	CcSEcCtD
Labetalol—Palpitations—Capecitabine—prostate cancer	0.000126	0.000446	CcSEcCtD
Labetalol—Loss of consciousness—Capecitabine—prostate cancer	0.000126	0.000444	CcSEcCtD
Labetalol—Asthenia—Mitoxantrone—prostate cancer	0.000125	0.000442	CcSEcCtD
Labetalol—Fatigue—Etoposide—prostate cancer	0.000125	0.000441	CcSEcCtD
Labetalol—Jaundice—Epirubicin—prostate cancer	0.000124	0.000439	CcSEcCtD
Labetalol—Constipation—Etoposide—prostate cancer	0.000124	0.000438	CcSEcCtD
Labetalol—Pain—Etoposide—prostate cancer	0.000124	0.000438	CcSEcCtD
Labetalol—Dizziness—Estradiol—prostate cancer	0.000124	0.000437	CcSEcCtD
Labetalol—Dysuria—Doxorubicin—prostate cancer	0.000124	0.000437	CcSEcCtD
Labetalol—Hypertension—Capecitabine—prostate cancer	0.000123	0.000436	CcSEcCtD
Labetalol—Sweating—Epirubicin—prostate cancer	0.000122	0.000431	CcSEcCtD
Labetalol—Confusional state—Docetaxel—prostate cancer	0.000121	0.000429	CcSEcCtD
Labetalol—Oedema—Docetaxel—prostate cancer	0.00012	0.000425	CcSEcCtD
Labetalol—Anaphylactic shock—Docetaxel—prostate cancer	0.00012	0.000425	CcSEcCtD
Labetalol—Discomfort—Capecitabine—prostate cancer	0.00012	0.000425	CcSEcCtD
Labetalol—Epistaxis—Epirubicin—prostate cancer	0.00012	0.000424	CcSEcCtD
Labetalol—Vision blurred—Prednisone—prostate cancer	0.00012	0.000424	CcSEcCtD
Labetalol—Tolterodine—CYP3A4—prostate cancer	0.00012	0.0152	CrCbGaD
Labetalol—Feeling abnormal—Etoposide—prostate cancer	0.000119	0.000422	CcSEcCtD
Labetalol—Diarrhoea—Mitoxantrone—prostate cancer	0.000119	0.000421	CcSEcCtD
Labetalol—Vomiting—Estradiol—prostate cancer	0.000119	0.00042	CcSEcCtD
Labetalol—Agranulocytosis—Epirubicin—prostate cancer	0.000119	0.00042	CcSEcCtD
Labetalol—Gastrointestinal pain—Etoposide—prostate cancer	0.000119	0.000419	CcSEcCtD
Labetalol—Shock—Docetaxel—prostate cancer	0.000119	0.000419	CcSEcCtD
Labetalol—Ill-defined disorder—Prednisone—prostate cancer	0.000118	0.000417	CcSEcCtD
Labetalol—Rash—Estradiol—prostate cancer	0.000118	0.000416	CcSEcCtD
Labetalol—Drowsiness—Doxorubicin—prostate cancer	0.000118	0.000416	CcSEcCtD
Labetalol—Dermatitis—Estradiol—prostate cancer	0.000118	0.000416	CcSEcCtD
Labetalol—Confusional state—Capecitabine—prostate cancer	0.000118	0.000415	CcSEcCtD
Labetalol—Headache—Estradiol—prostate cancer	0.000117	0.000414	CcSEcCtD
Labetalol—Oedema—Capecitabine—prostate cancer	0.000117	0.000412	CcSEcCtD
Labetalol—Bradycardia—Epirubicin—prostate cancer	0.000116	0.000411	CcSEcCtD
Labetalol—Angioedema—Prednisone—prostate cancer	0.000116	0.000411	CcSEcCtD
Labetalol—Urticaria—Etoposide—prostate cancer	0.000115	0.000407	CcSEcCtD
Labetalol—Jaundice—Doxorubicin—prostate cancer	0.000115	0.000406	CcSEcCtD
Labetalol—Malaise—Prednisone—prostate cancer	0.000115	0.000405	CcSEcCtD
Labetalol—Shock—Capecitabine—prostate cancer	0.000115	0.000405	CcSEcCtD
Labetalol—Abdominal pain—Etoposide—prostate cancer	0.000115	0.000405	CcSEcCtD
Labetalol—Body temperature increased—Etoposide—prostate cancer	0.000115	0.000405	CcSEcCtD
Labetalol—Vertigo—Prednisone—prostate cancer	0.000114	0.000404	CcSEcCtD
Labetalol—Hepatitis—Epirubicin—prostate cancer	0.000114	0.000404	CcSEcCtD
Labetalol—Syncope—Prednisone—prostate cancer	0.000114	0.000403	CcSEcCtD
Labetalol—Hypoaesthesia—Epirubicin—prostate cancer	0.000114	0.000402	CcSEcCtD
Labetalol—Sweating—Doxorubicin—prostate cancer	0.000113	0.000399	CcSEcCtD
Labetalol—Hyperhidrosis—Capecitabine—prostate cancer	0.000113	0.000398	CcSEcCtD
Labetalol—Oedema peripheral—Epirubicin—prostate cancer	0.000113	0.000398	CcSEcCtD
Labetalol—Hypotension—Docetaxel—prostate cancer	0.000113	0.000398	CcSEcCtD
Labetalol—Loss of consciousness—Prednisone—prostate cancer	0.000112	0.000395	CcSEcCtD
Labetalol—Epistaxis—Doxorubicin—prostate cancer	0.000111	0.000393	CcSEcCtD
Labetalol—Nausea—Estradiol—prostate cancer	0.000111	0.000392	CcSEcCtD
Labetalol—Vomiting—Mitoxantrone—prostate cancer	0.000111	0.000391	CcSEcCtD
Labetalol—Visual impairment—Epirubicin—prostate cancer	0.00011	0.000389	CcSEcCtD
Labetalol—Agranulocytosis—Doxorubicin—prostate cancer	0.00011	0.000389	CcSEcCtD
Labetalol—Hypertension—Prednisone—prostate cancer	0.00011	0.000388	CcSEcCtD
Labetalol—Rash—Mitoxantrone—prostate cancer	0.00011	0.000388	CcSEcCtD
Labetalol—Dermatitis—Mitoxantrone—prostate cancer	0.00011	0.000388	CcSEcCtD
Labetalol—Headache—Mitoxantrone—prostate cancer	0.000109	0.000386	CcSEcCtD
Labetalol—Hypotension—Capecitabine—prostate cancer	0.000109	0.000385	CcSEcCtD
Labetalol—Paraesthesia—Docetaxel—prostate cancer	0.000108	0.000382	CcSEcCtD
Labetalol—Bradycardia—Doxorubicin—prostate cancer	0.000108	0.00038	CcSEcCtD
Labetalol—Dyspnoea—Docetaxel—prostate cancer	0.000107	0.000379	CcSEcCtD
Labetalol—Somnolence—Docetaxel—prostate cancer	0.000107	0.000378	CcSEcCtD
Labetalol—Discomfort—Prednisone—prostate cancer	0.000107	0.000378	CcSEcCtD
Labetalol—Hypersensitivity—Etoposide—prostate cancer	0.000107	0.000377	CcSEcCtD
Labetalol—Flushing—Epirubicin—prostate cancer	0.000106	0.000375	CcSEcCtD
Labetalol—Dyspepsia—Docetaxel—prostate cancer	0.000106	0.000375	CcSEcCtD
Labetalol—Hepatitis—Doxorubicin—prostate cancer	0.000106	0.000374	CcSEcCtD
Labetalol—Hypoaesthesia—Doxorubicin—prostate cancer	0.000105	0.000372	CcSEcCtD
Labetalol—Paraesthesia—Capecitabine—prostate cancer	0.000105	0.00037	CcSEcCtD
Labetalol—Oedema peripheral—Doxorubicin—prostate cancer	0.000104	0.000368	CcSEcCtD
Labetalol—Asthenia—Etoposide—prostate cancer	0.000104	0.000367	CcSEcCtD
Labetalol—Dyspnoea—Capecitabine—prostate cancer	0.000104	0.000367	CcSEcCtD
Labetalol—Anaphylactic shock—Prednisone—prostate cancer	0.000104	0.000367	CcSEcCtD
Labetalol—Oedema—Prednisone—prostate cancer	0.000104	0.000367	CcSEcCtD
Labetalol—Fatigue—Docetaxel—prostate cancer	0.000104	0.000367	CcSEcCtD
Labetalol—Nausea—Mitoxantrone—prostate cancer	0.000103	0.000366	CcSEcCtD
Labetalol—Constipation—Docetaxel—prostate cancer	0.000103	0.000364	CcSEcCtD
Labetalol—Pain—Docetaxel—prostate cancer	0.000103	0.000364	CcSEcCtD
Labetalol—Dyspepsia—Capecitabine—prostate cancer	0.000103	0.000363	CcSEcCtD
Labetalol—Pruritus—Etoposide—prostate cancer	0.000103	0.000362	CcSEcCtD
Labetalol—Shock—Prednisone—prostate cancer	0.000102	0.000361	CcSEcCtD
Labetalol—Visual impairment—Doxorubicin—prostate cancer	0.000102	0.00036	CcSEcCtD
Labetalol—Propafenone—CYP3A4—prostate cancer	0.000102	0.0129	CrCbGaD
Labetalol—Alopecia—Epirubicin—prostate cancer	0.000101	0.000357	CcSEcCtD
Labetalol—Fatigue—Capecitabine—prostate cancer	0.000101	0.000355	CcSEcCtD
Labetalol—Hyperhidrosis—Prednisone—prostate cancer	0.0001	0.000355	CcSEcCtD
Labetalol—Mental disorder—Epirubicin—prostate cancer	0.0001	0.000354	CcSEcCtD
Labetalol—Pain—Capecitabine—prostate cancer	9.97e-05	0.000352	CcSEcCtD
Labetalol—Constipation—Capecitabine—prostate cancer	9.97e-05	0.000352	CcSEcCtD
Labetalol—Erythema—Epirubicin—prostate cancer	9.95e-05	0.000352	CcSEcCtD
Labetalol—Feeling abnormal—Docetaxel—prostate cancer	9.93e-05	0.000351	CcSEcCtD
Labetalol—Diarrhoea—Etoposide—prostate cancer	9.92e-05	0.00035	CcSEcCtD
Labetalol—Gastrointestinal pain—Docetaxel—prostate cancer	9.85e-05	0.000348	CcSEcCtD
Labetalol—Flushing—Doxorubicin—prostate cancer	9.82e-05	0.000347	CcSEcCtD
Labetalol—Feeling abnormal—Capecitabine—prostate cancer	9.61e-05	0.000339	CcSEcCtD
Labetalol—Dizziness—Etoposide—prostate cancer	9.58e-05	0.000339	CcSEcCtD
Labetalol—Muscle spasms—Epirubicin—prostate cancer	9.57e-05	0.000338	CcSEcCtD
Labetalol—Gastrointestinal pain—Capecitabine—prostate cancer	9.54e-05	0.000337	CcSEcCtD
Labetalol—Body temperature increased—Docetaxel—prostate cancer	9.52e-05	0.000336	CcSEcCtD
Labetalol—Abdominal pain—Docetaxel—prostate cancer	9.52e-05	0.000336	CcSEcCtD
Labetalol—Vision blurred—Epirubicin—prostate cancer	9.38e-05	0.000331	CcSEcCtD
Labetalol—Alopecia—Doxorubicin—prostate cancer	9.35e-05	0.00033	CcSEcCtD
Labetalol—Paraesthesia—Prednisone—prostate cancer	9.33e-05	0.000329	CcSEcCtD
Labetalol—Mental disorder—Doxorubicin—prostate cancer	9.27e-05	0.000327	CcSEcCtD
Labetalol—Urticaria—Capecitabine—prostate cancer	9.26e-05	0.000327	CcSEcCtD
Labetalol—Ill-defined disorder—Epirubicin—prostate cancer	9.24e-05	0.000326	CcSEcCtD
Labetalol—Abdominal pain—Capecitabine—prostate cancer	9.22e-05	0.000326	CcSEcCtD
Labetalol—Body temperature increased—Capecitabine—prostate cancer	9.22e-05	0.000326	CcSEcCtD
Labetalol—Vomiting—Etoposide—prostate cancer	9.21e-05	0.000325	CcSEcCtD
Labetalol—Erythema—Doxorubicin—prostate cancer	9.21e-05	0.000325	CcSEcCtD
Labetalol—Dyspepsia—Prednisone—prostate cancer	9.14e-05	0.000323	CcSEcCtD
Labetalol—Rash—Etoposide—prostate cancer	9.14e-05	0.000323	CcSEcCtD
Labetalol—Dermatitis—Etoposide—prostate cancer	9.13e-05	0.000322	CcSEcCtD
Labetalol—Headache—Etoposide—prostate cancer	9.08e-05	0.000321	CcSEcCtD
Labetalol—Malaise—Epirubicin—prostate cancer	8.98e-05	0.000317	CcSEcCtD
Labetalol—Fatigue—Prednisone—prostate cancer	8.96e-05	0.000316	CcSEcCtD
Labetalol—Vertigo—Epirubicin—prostate cancer	8.94e-05	0.000316	CcSEcCtD
Labetalol—Syncope—Epirubicin—prostate cancer	8.93e-05	0.000315	CcSEcCtD
Labetalol—Constipation—Prednisone—prostate cancer	8.88e-05	0.000314	CcSEcCtD
Labetalol—Hypersensitivity—Docetaxel—prostate cancer	8.87e-05	0.000313	CcSEcCtD
Labetalol—Muscle spasms—Doxorubicin—prostate cancer	8.86e-05	0.000313	CcSEcCtD
Labetalol—Palpitations—Epirubicin—prostate cancer	8.8e-05	0.000311	CcSEcCtD
Labetalol—Loss of consciousness—Epirubicin—prostate cancer	8.75e-05	0.000309	CcSEcCtD
Labetalol—Flurbiprofen—PTGS2—prostate cancer	8.69e-05	0.011	CrCbGaD
Labetalol—Vision blurred—Doxorubicin—prostate cancer	8.68e-05	0.000307	CcSEcCtD
Labetalol—Asthenia—Docetaxel—prostate cancer	8.64e-05	0.000305	CcSEcCtD
Labetalol—Nausea—Etoposide—prostate cancer	8.61e-05	0.000304	CcSEcCtD
Labetalol—Hypertension—Epirubicin—prostate cancer	8.59e-05	0.000304	CcSEcCtD
Labetalol—Hypersensitivity—Capecitabine—prostate cancer	8.59e-05	0.000303	CcSEcCtD
Labetalol—Feeling abnormal—Prednisone—prostate cancer	8.56e-05	0.000302	CcSEcCtD
Labetalol—Ill-defined disorder—Doxorubicin—prostate cancer	8.55e-05	0.000302	CcSEcCtD
Labetalol—Pruritus—Docetaxel—prostate cancer	8.52e-05	0.000301	CcSEcCtD
Labetalol—Gastrointestinal pain—Prednisone—prostate cancer	8.49e-05	0.0003	CcSEcCtD
Labetalol—Discomfort—Epirubicin—prostate cancer	8.37e-05	0.000296	CcSEcCtD
Labetalol—Asthenia—Capecitabine—prostate cancer	8.37e-05	0.000296	CcSEcCtD
Labetalol—Malaise—Doxorubicin—prostate cancer	8.31e-05	0.000293	CcSEcCtD
Labetalol—Vertigo—Doxorubicin—prostate cancer	8.28e-05	0.000292	CcSEcCtD
Labetalol—Syncope—Doxorubicin—prostate cancer	8.26e-05	0.000292	CcSEcCtD
Labetalol—Urticaria—Prednisone—prostate cancer	8.25e-05	0.000291	CcSEcCtD
Labetalol—Pruritus—Capecitabine—prostate cancer	8.25e-05	0.000291	CcSEcCtD
Labetalol—Diarrhoea—Docetaxel—prostate cancer	8.24e-05	0.000291	CcSEcCtD
Labetalol—Abdominal pain—Prednisone—prostate cancer	8.21e-05	0.00029	CcSEcCtD
Labetalol—Body temperature increased—Prednisone—prostate cancer	8.21e-05	0.00029	CcSEcCtD
Labetalol—Confusional state—Epirubicin—prostate cancer	8.19e-05	0.000289	CcSEcCtD
Labetalol—Palpitations—Doxorubicin—prostate cancer	8.14e-05	0.000288	CcSEcCtD
Labetalol—Oedema—Epirubicin—prostate cancer	8.12e-05	0.000287	CcSEcCtD
Labetalol—Anaphylactic shock—Epirubicin—prostate cancer	8.12e-05	0.000287	CcSEcCtD
Labetalol—Loss of consciousness—Doxorubicin—prostate cancer	8.1e-05	0.000286	CcSEcCtD
Labetalol—Shock—Epirubicin—prostate cancer	7.99e-05	0.000282	CcSEcCtD
Labetalol—Diarrhoea—Capecitabine—prostate cancer	7.98e-05	0.000282	CcSEcCtD
Labetalol—Dizziness—Docetaxel—prostate cancer	7.96e-05	0.000281	CcSEcCtD
Labetalol—Hypertension—Doxorubicin—prostate cancer	7.95e-05	0.000281	CcSEcCtD
Labetalol—Ketoprofen—PTGS2—prostate cancer	7.86e-05	0.00998	CrCbGaD
Labetalol—Hyperhidrosis—Epirubicin—prostate cancer	7.85e-05	0.000277	CcSEcCtD
Labetalol—Discomfort—Doxorubicin—prostate cancer	7.75e-05	0.000274	CcSEcCtD
Labetalol—Dizziness—Capecitabine—prostate cancer	7.71e-05	0.000272	CcSEcCtD
Labetalol—Vomiting—Docetaxel—prostate cancer	7.66e-05	0.000271	CcSEcCtD
Labetalol—Hypersensitivity—Prednisone—prostate cancer	7.65e-05	0.00027	CcSEcCtD
Labetalol—Rash—Docetaxel—prostate cancer	7.59e-05	0.000268	CcSEcCtD
Labetalol—Hypotension—Epirubicin—prostate cancer	7.59e-05	0.000268	CcSEcCtD
Labetalol—Dermatitis—Docetaxel—prostate cancer	7.59e-05	0.000268	CcSEcCtD
Labetalol—Confusional state—Doxorubicin—prostate cancer	7.58e-05	0.000268	CcSEcCtD
Labetalol—Headache—Docetaxel—prostate cancer	7.55e-05	0.000267	CcSEcCtD
Labetalol—Anaphylactic shock—Doxorubicin—prostate cancer	7.52e-05	0.000266	CcSEcCtD
Labetalol—Oedema—Doxorubicin—prostate cancer	7.52e-05	0.000266	CcSEcCtD
Labetalol—Asthenia—Prednisone—prostate cancer	7.45e-05	0.000263	CcSEcCtD
Labetalol—Vomiting—Capecitabine—prostate cancer	7.41e-05	0.000262	CcSEcCtD
Labetalol—Shock—Doxorubicin—prostate cancer	7.4e-05	0.000261	CcSEcCtD
Labetalol—Rash—Capecitabine—prostate cancer	7.35e-05	0.00026	CcSEcCtD
Labetalol—Pruritus—Prednisone—prostate cancer	7.35e-05	0.00026	CcSEcCtD
Labetalol—Dermatitis—Capecitabine—prostate cancer	7.35e-05	0.000259	CcSEcCtD
Labetalol—Headache—Capecitabine—prostate cancer	7.31e-05	0.000258	CcSEcCtD
Labetalol—Paraesthesia—Epirubicin—prostate cancer	7.29e-05	0.000258	CcSEcCtD
Labetalol—Hyperhidrosis—Doxorubicin—prostate cancer	7.27e-05	0.000257	CcSEcCtD
Labetalol—Dyspnoea—Epirubicin—prostate cancer	7.24e-05	0.000256	CcSEcCtD
Labetalol—Somnolence—Epirubicin—prostate cancer	7.22e-05	0.000255	CcSEcCtD
Labetalol—Nausea—Docetaxel—prostate cancer	7.15e-05	0.000253	CcSEcCtD
Labetalol—Dyspepsia—Epirubicin—prostate cancer	7.15e-05	0.000253	CcSEcCtD
Labetalol—Diarrhoea—Prednisone—prostate cancer	7.11e-05	0.000251	CcSEcCtD
Labetalol—Hypotension—Doxorubicin—prostate cancer	7.02e-05	0.000248	CcSEcCtD
Labetalol—Fatigue—Epirubicin—prostate cancer	7e-05	0.000247	CcSEcCtD
Labetalol—Constipation—Epirubicin—prostate cancer	6.95e-05	0.000245	CcSEcCtD
Labetalol—Pain—Epirubicin—prostate cancer	6.95e-05	0.000245	CcSEcCtD
Labetalol—Nausea—Capecitabine—prostate cancer	6.93e-05	0.000245	CcSEcCtD
Labetalol—Dizziness—Prednisone—prostate cancer	6.87e-05	0.000243	CcSEcCtD
Labetalol—Paraesthesia—Doxorubicin—prostate cancer	6.75e-05	0.000238	CcSEcCtD
Labetalol—Dyspnoea—Doxorubicin—prostate cancer	6.7e-05	0.000237	CcSEcCtD
Labetalol—Feeling abnormal—Epirubicin—prostate cancer	6.69e-05	0.000236	CcSEcCtD
Labetalol—Somnolence—Doxorubicin—prostate cancer	6.68e-05	0.000236	CcSEcCtD
Labetalol—Gastrointestinal pain—Epirubicin—prostate cancer	6.64e-05	0.000235	CcSEcCtD
Labetalol—Dyspepsia—Doxorubicin—prostate cancer	6.62e-05	0.000234	CcSEcCtD
Labetalol—Vomiting—Prednisone—prostate cancer	6.6e-05	0.000233	CcSEcCtD
Labetalol—Rash—Prednisone—prostate cancer	6.55e-05	0.000231	CcSEcCtD
Labetalol—Dermatitis—Prednisone—prostate cancer	6.54e-05	0.000231	CcSEcCtD
Labetalol—Headache—Prednisone—prostate cancer	6.51e-05	0.00023	CcSEcCtD
Labetalol—Fatigue—Doxorubicin—prostate cancer	6.48e-05	0.000229	CcSEcCtD
Labetalol—Urticaria—Epirubicin—prostate cancer	6.45e-05	0.000228	CcSEcCtD
Labetalol—Pain—Doxorubicin—prostate cancer	6.43e-05	0.000227	CcSEcCtD
Labetalol—Constipation—Doxorubicin—prostate cancer	6.43e-05	0.000227	CcSEcCtD
Labetalol—Abdominal pain—Epirubicin—prostate cancer	6.42e-05	0.000227	CcSEcCtD
Labetalol—Body temperature increased—Epirubicin—prostate cancer	6.42e-05	0.000227	CcSEcCtD
Labetalol—Feeling abnormal—Doxorubicin—prostate cancer	6.19e-05	0.000219	CcSEcCtD
Labetalol—Nausea—Prednisone—prostate cancer	6.17e-05	0.000218	CcSEcCtD
Labetalol—Gastrointestinal pain—Doxorubicin—prostate cancer	6.15e-05	0.000217	CcSEcCtD
Labetalol—Hypersensitivity—Epirubicin—prostate cancer	5.99e-05	0.000211	CcSEcCtD
Labetalol—Urticaria—Doxorubicin—prostate cancer	5.97e-05	0.000211	CcSEcCtD
Labetalol—Body temperature increased—Doxorubicin—prostate cancer	5.94e-05	0.00021	CcSEcCtD
Labetalol—Abdominal pain—Doxorubicin—prostate cancer	5.94e-05	0.00021	CcSEcCtD
Labetalol—Asthenia—Epirubicin—prostate cancer	5.83e-05	0.000206	CcSEcCtD
Labetalol—Pruritus—Epirubicin—prostate cancer	5.75e-05	0.000203	CcSEcCtD
Labetalol—Diarrhoea—Epirubicin—prostate cancer	5.56e-05	0.000196	CcSEcCtD
Labetalol—Hypersensitivity—Doxorubicin—prostate cancer	5.54e-05	0.000196	CcSEcCtD
Labetalol—Asthenia—Doxorubicin—prostate cancer	5.39e-05	0.000191	CcSEcCtD
Labetalol—Dizziness—Epirubicin—prostate cancer	5.37e-05	0.00019	CcSEcCtD
Labetalol—Pruritus—Doxorubicin—prostate cancer	5.32e-05	0.000188	CcSEcCtD
Labetalol—Vomiting—Epirubicin—prostate cancer	5.17e-05	0.000182	CcSEcCtD
Labetalol—Diarrhoea—Doxorubicin—prostate cancer	5.14e-05	0.000182	CcSEcCtD
Labetalol—Rash—Epirubicin—prostate cancer	5.12e-05	0.000181	CcSEcCtD
Labetalol—Dermatitis—Epirubicin—prostate cancer	5.12e-05	0.000181	CcSEcCtD
Labetalol—Headache—Epirubicin—prostate cancer	5.09e-05	0.00018	CcSEcCtD
Labetalol—Dizziness—Doxorubicin—prostate cancer	4.97e-05	0.000176	CcSEcCtD
Labetalol—Nausea—Epirubicin—prostate cancer	4.83e-05	0.00017	CcSEcCtD
Labetalol—Vomiting—Doxorubicin—prostate cancer	4.78e-05	0.000169	CcSEcCtD
Labetalol—Rash—Doxorubicin—prostate cancer	4.74e-05	0.000167	CcSEcCtD
Labetalol—Dermatitis—Doxorubicin—prostate cancer	4.74e-05	0.000167	CcSEcCtD
Labetalol—Headache—Doxorubicin—prostate cancer	4.71e-05	0.000166	CcSEcCtD
Labetalol—Nausea—Doxorubicin—prostate cancer	4.47e-05	0.000158	CcSEcCtD
Labetalol—CYP2D6—Metabolism—SULT1A1—prostate cancer	1.64e-05	0.000197	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	1.63e-05	0.000195	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CASP9—prostate cancer	1.63e-05	0.000195	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	1.61e-05	0.000193	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NGFR—prostate cancer	1.61e-05	0.000193	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GSK3B—prostate cancer	1.61e-05	0.000192	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTA1—prostate cancer	1.61e-05	0.000192	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	1.59e-05	0.000191	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	1.59e-05	0.000191	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HSD3B2—prostate cancer	1.59e-05	0.00019	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTO1—prostate cancer	1.59e-05	0.00019	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NAT2—prostate cancer	1.59e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—INS—prostate cancer	1.58e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	1.58e-05	0.000189	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NGFR—prostate cancer	1.58e-05	0.000189	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	1.56e-05	0.000187	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CREBBP—prostate cancer	1.55e-05	0.000186	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IGF1—prostate cancer	1.53e-05	0.000184	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGF10—prostate cancer	1.53e-05	0.000183	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—EGFR—prostate cancer	1.52e-05	0.000183	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PLCB2—prostate cancer	1.52e-05	0.000182	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—LRP2—prostate cancer	1.52e-05	0.000182	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP2C18—prostate cancer	1.52e-05	0.000182	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	1.51e-05	0.000182	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGF10—prostate cancer	1.5e-05	0.000179	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	1.49e-05	0.000179	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—P4HB—prostate cancer	1.49e-05	0.000179	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	1.49e-05	0.000178	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MAP2K1—prostate cancer	1.48e-05	0.000178	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	1.48e-05	0.000177	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—VAV3—prostate cancer	1.48e-05	0.000177	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CD—prostate cancer	1.47e-05	0.000176	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	1.46e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PIK3CA—prostate cancer	1.46e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	1.46e-05	0.000174	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	1.46e-05	0.000174	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SERPINE1—prostate cancer	1.46e-05	0.000174	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC22A1—prostate cancer	1.45e-05	0.000174	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	1.45e-05	0.000173	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—VAV3—prostate cancer	1.44e-05	0.000173	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—KRAS—prostate cancer	1.44e-05	0.000173	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	1.43e-05	0.000172	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	1.42e-05	0.000171	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	1.42e-05	0.00017	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SULT2A1—prostate cancer	1.41e-05	0.00017	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FGF2—prostate cancer	1.41e-05	0.000169	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	1.4e-05	0.000168	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MED12—prostate cancer	1.39e-05	0.000167	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOS3—prostate cancer	1.39e-05	0.000167	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.39e-05	0.000166	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GNG5—prostate cancer	1.38e-05	0.000165	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	1.37e-05	0.000164	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.36e-05	0.000163	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1.36e-05	0.000163	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—JAK2—prostate cancer	1.35e-05	0.000162	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	1.34e-05	0.000161	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	1.33e-05	0.00016	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA3—prostate cancer	1.33e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	1.33e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PIK3CA—prostate cancer	1.32e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MDM2—prostate cancer	1.32e-05	0.000158	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LPL—prostate cancer	1.31e-05	0.000157	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	1.3e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	1.3e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ERBB2—prostate cancer	1.3e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	1.29e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LPL—prostate cancer	1.28e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CB—prostate cancer	1.28e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	1.27e-05	0.000153	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	1.27e-05	0.000153	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HPGDS—prostate cancer	1.27e-05	0.000152	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	1.27e-05	0.000152	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP2C19—prostate cancer	1.26e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	1.26e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	1.24e-05	0.000149	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	1.24e-05	0.000148	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CXCL8—prostate cancer	1.23e-05	0.000148	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ACHE—prostate cancer	1.23e-05	0.000147	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTT1—prostate cancer	1.23e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	1.23e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	1.23e-05	0.000147	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP2A6—prostate cancer	1.22e-05	0.000146	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	1.21e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1B—prostate cancer	1.2e-05	0.000144	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	1.2e-05	0.000144	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	1.2e-05	0.000144	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—AKT1—prostate cancer	1.19e-05	0.000143	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL2—prostate cancer	1.18e-05	0.000142	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKR1C3—prostate cancer	1.18e-05	0.000142	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CASP3—prostate cancer	1.18e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TERT—prostate cancer	1.18e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL2—prostate cancer	1.18e-05	0.000141	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PRKACB—prostate cancer	1.18e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6—prostate cancer	1.17e-05	0.00014	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP17A1—prostate cancer	1.16e-05	0.00014	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL2—prostate cancer	1.16e-05	0.000139	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TERT—prostate cancer	1.15e-05	0.000138	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CCND1—prostate cancer	1.15e-05	0.000138	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CTNNB1—prostate cancer	1.14e-05	0.000136	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	1.13e-05	0.000135	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MMP9—prostate cancer	1.11e-05	0.000134	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1A—prostate cancer	1.11e-05	0.000133	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA2—prostate cancer	1.11e-05	0.000133	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTEN—prostate cancer	1.11e-05	0.000133	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	1.1e-05	0.000132	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LEP—prostate cancer	1.1e-05	0.000132	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CAV1—prostate cancer	1.09e-05	0.000131	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—AKT1—prostate cancer	1.08e-05	0.00013	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KDR—prostate cancer	1.08e-05	0.000129	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LEP—prostate cancer	1.08e-05	0.000129	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CAV1—prostate cancer	1.07e-05	0.000128	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.06e-05	0.000127	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EP300—prostate cancer	1.06e-05	0.000127	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KDR—prostate cancer	1.05e-05	0.000126	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ESR1—prostate cancer	1.05e-05	0.000126	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.03e-05	0.000124	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ESR1—prostate cancer	1.03e-05	0.000123	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SRC—prostate cancer	1.03e-05	0.000123	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BAD—prostate cancer	1.03e-05	0.000123	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NQO1—prostate cancer	1.02e-05	0.000123	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TH—prostate cancer	1.01e-05	0.000121	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BAD—prostate cancer	1e-05	0.00012	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—VEGFA—prostate cancer	1e-05	0.00012	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP3A4—prostate cancer	9.97e-06	0.00012	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—APC—prostate cancer	9.93e-06	0.000119	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	9.93e-06	0.000119	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—STAT3—prostate cancer	9.91e-06	0.000119	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGF—prostate cancer	9.82e-06	0.000118	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IRS1—prostate cancer	9.82e-06	0.000118	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1B1—prostate cancer	9.8e-06	0.000118	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	9.72e-06	0.000116	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—APC—prostate cancer	9.72e-06	0.000116	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGF—prostate cancer	9.61e-06	0.000115	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IRS1—prostate cancer	9.61e-06	0.000115	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	9.53e-06	0.000114	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GGT1—prostate cancer	9.5e-06	0.000114	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—INS—prostate cancer	9.4e-06	0.000113	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA1—prostate cancer	9.35e-06	0.000112	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	9.33e-06	0.000112	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP19A1—prostate cancer	9.22e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	9.21e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MYC—prostate cancer	9.21e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—INS—prostate cancer	9.2e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TGFB1—prostate cancer	9.19e-06	0.00011	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1—prostate cancer	9.1e-06	0.000109	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	9.05e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	9.01e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EGFR—prostate cancer	9.01e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1—prostate cancer	8.9e-06	0.000107	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—RXRA—prostate cancer	8.9e-06	0.000107	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	8.85e-06	0.000106	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	8.79e-06	0.000105	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	8.73e-06	0.000105	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	8.65e-06	0.000104	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	8.64e-06	0.000104	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	8.6e-06	0.000103	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—COMT—prostate cancer	8.57e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	8.55e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	8.54e-06	0.000102	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTP1—prostate cancer	8.53e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KRAS—prostate cancer	8.51e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	8.46e-06	0.000101	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	8.45e-06	0.000101	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ITPR1—prostate cancer	8.39e-06	0.000101	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	8.36e-06	0.0001	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGF2—prostate cancer	8.36e-06	0.0001	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOS3—prostate cancer	8.25e-06	9.88e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGF2—prostate cancer	8.18e-06	9.8e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOS3—prostate cancer	8.07e-06	9.67e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—JAK2—prostate cancer	8.02e-06	9.61e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TYMS—prostate cancer	7.93e-06	9.5e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	7.86e-06	9.41e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—JAK2—prostate cancer	7.84e-06	9.4e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTM1—prostate cancer	7.84e-06	9.39e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MDM2—prostate cancer	7.82e-06	9.38e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CA—prostate cancer	7.82e-06	9.37e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	7.71e-06	9.24e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—LPL—prostate cancer	7.69e-06	9.22e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	7.68e-06	9.21e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MDM2—prostate cancer	7.65e-06	9.17e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	7.61e-06	9.12e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TP53—prostate cancer	7.56e-06	9.06e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	7.55e-06	9.04e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	7.45e-06	8.92e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1A1—prostate cancer	7.43e-06	8.91e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ERCC2—prostate cancer	7.37e-06	8.83e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	7.32e-06	8.77e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	7.16e-06	8.58e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	7.14e-06	8.56e-05	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	7.07e-06	8.47e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CASP3—prostate cancer	7e-06	8.39e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL2—prostate cancer	6.99e-06	8.38e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	6.99e-06	8.37e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6—prostate cancer	6.96e-06	8.34e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTHFR—prostate cancer	6.93e-06	8.3e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6—prostate cancer	6.92e-06	8.3e-05	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	6.91e-06	8.28e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CASP3—prostate cancer	6.85e-06	8.21e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL2—prostate cancer	6.84e-06	8.2e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CCND1—prostate cancer	6.82e-06	8.17e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6—prostate cancer	6.8e-06	8.15e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PPARA—prostate cancer	6.8e-06	8.14e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	6.75e-06	8.09e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CCND1—prostate cancer	6.67e-06	7.99e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MMP9—prostate cancer	6.62e-06	7.93e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	6.6e-06	7.91e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	6.59e-06	7.9e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTEN—prostate cancer	6.58e-06	7.88e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MMP9—prostate cancer	6.47e-06	7.76e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	6.45e-06	7.73e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTEN—prostate cancer	6.43e-06	7.71e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	6.42e-06	7.69e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CAV1—prostate cancer	6.39e-06	7.66e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKT1—prostate cancer	6.39e-06	7.65e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	6.28e-06	7.52e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EP300—prostate cancer	6.27e-06	7.52e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EP300—prostate cancer	6.14e-06	7.35e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SRC—prostate cancer	6.1e-06	7.31e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SRC—prostate cancer	5.97e-06	7.15e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	5.94e-06	7.12e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—STAT3—prostate cancer	5.88e-06	7.05e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CG—prostate cancer	5.82e-06	6.98e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	5.81e-06	6.97e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—STAT3—prostate cancer	5.75e-06	6.9e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—INS—prostate cancer	5.51e-06	6.6e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MYC—prostate cancer	5.47e-06	6.55e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	5.45e-06	6.54e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CREBBP—prostate cancer	5.4e-06	6.47e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MYC—prostate cancer	5.35e-06	6.41e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGFR—prostate cancer	5.35e-06	6.41e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	5.33e-06	6.39e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGFR—prostate cancer	5.23e-06	6.27e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CD—prostate cancer	5.12e-06	6.13e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KRAS—prostate cancer	5.05e-06	6.05e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KRAS—prostate cancer	4.94e-06	5.92e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NOS3—prostate cancer	4.83e-06	5.79e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	4.64e-06	5.56e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	4.54e-06	5.44e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TP53—prostate cancer	4.49e-06	5.38e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CB—prostate cancer	4.46e-06	5.34e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTGS2—prostate cancer	4.42e-06	5.3e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TP53—prostate cancer	4.39e-06	5.26e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6—prostate cancer	4.11e-06	4.92e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6—prostate cancer	4.02e-06	4.82e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTEN—prostate cancer	3.85e-06	4.62e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKT1—prostate cancer	3.79e-06	4.54e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKT1—prostate cancer	3.71e-06	4.44e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—EP300—prostate cancer	3.68e-06	4.4e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.72e-06	3.26e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKT1—prostate cancer	2.22e-06	2.66e-05	CbGpPWpGaD
